Lídia Robert
University of California, Los Angeles · 88 works · 12,698 citations · h-index 23
Top works
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
- Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
- Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress
- CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire
- Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
- Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
- Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy
- Combining Targeted Therapy With Immunotherapy in BRAF-Mutant Melanoma: Promise and Challenges
- Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes
- Risk-Adapted Treatment in Clinical Stage I Testicular Seminoma: The Third Spanish Germ Cell Cancer Group Study
- Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells
- MITF drives endolysosomal biogenesis and potentiates Wnt signaling in melanoma cells
- Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
- Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance
- Immunotherapy Resistance by Inflammation-Induced Dedifferentiation
- Anti–PD-1 Therapy in Melanoma
- Multi-omic single-cell snapshots reveal multiple independent trajectories to drug tolerance in a melanoma cell line
- Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors
- Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma